Advanced

Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.

Palmason, Robert LU ; Lindén, Ola LU and Richter, Johan LU (2015) In BMC hematology 15. p.10-10
Abstract
Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
BMC hematology
volume
15
pages
10 - 10
external identifiers
  • PMID:26167286
ISSN
2052-1839
DOI
10.1186/s12878-015-0029-1
language
English
LU publication?
yes
id
bc4cae6d-1982-4514-9f40-0b6ae73f8f79 (old id 7749771)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26167286?dopt=Abstract
date added to LUP
2015-08-08 01:20:04
date last changed
2016-09-20 03:35:31
@misc{bc4cae6d-1982-4514-9f40-0b6ae73f8f79,
  abstract     = {Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib.},
  author       = {Palmason, Robert and Lindén, Ola and Richter, Johan},
  issn         = {2052-1839},
  language     = {eng},
  pages        = {10--10},
  series       = {BMC hematology},
  title        = {Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.},
  url          = {http://dx.doi.org/10.1186/s12878-015-0029-1},
  volume       = {15},
  year         = {2015},
}